Previous Close | 2.3300 |
Open | 2.3400 |
Bid | 2.3200 x 100 |
Ask | 2.3900 x 100 |
Day's Range | 2.3400 - 2.4300 |
52 Week Range | 1.6700 - 5.2500 |
Volume | |
Avg. Volume | 173,745 |
Market Cap | 95.22M |
Beta (5Y Monthly) | 1.82 |
PE Ratio (TTM) | 16.79 |
EPS (TTM) | 0.1400 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.25 |
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the “Convertible Debentures”) previously issued and sold to YA II PN, Ltd. (“Yorkville”) in March 2023. Sci
Oramed Pharmaceuticals ( NASDAQ:ORMP ) Full Year 2023 Results Key Financial Results Net income: US$5.53m (up from...
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.